Dr Joseph Frank Michalski, MD, MPH, MS in Chicago, IL - Medicare Student in an Organized Health Care Education/Training Program

Dr Joseph Frank Michalski, MD, MPH, MS is a medicare enrolled "Student In An Organized Health Care Education/training Program" physician in Chicago, Illinois. His current practice location is 820 S Wood St, Chicago, Illinois. You can reach out to his office (for appointments etc.) via phone at (516) 497-1888.

Dr Joseph Frank Michalski is licensed to practice in Illinois (license number 036.168255) and he also participates in the medicare program. He does not accept medicare assignments directly but he may accept medicare through third-party (refer to Reassignment section below) and may also prescribe medicare part D drugs. His NPI Number is 1013571736.

Contact Information

	Dr Joseph Frank Michalski, MD, MPH, MS
	820 S Wood St, Chicago, IL 60612-4325
	(516) 497-1888
	Not Available

Physician's Profile

Full Name	Dr Joseph Frank Michalski
Gender	Male
Speciality	Student In An Organized Health Care Education/training Program
Location	820 S Wood St, Chicago, Illinois
Accepts Medicare Assignments	Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs.

NPI Data:

NPI Number: 1013571736
Provider Enumeration Date: 04/29/2019
Last Update Date: 01/12/2024

Medicare PECOS Information:

PECOS PAC ID: 8921456591
Enrollment ID: I20231121002438

Medical Identifiers

Medical identifiers for Dr Joseph Frank Michalski such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1013571736	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	ME165552 (Florida)	Secondary
390200000X	Student In An Organized Health Care Education/training Program	(* (Not Available))	Secondary
390200000X	Student In An Organized Health Care Education/training Program	036.168255 (Illinois)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Joseph Frank Michalski is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Joseph Frank Michalski, MD, MPH, MS 17 Davis Blvd Ste 308, Tampa, FL 33606-3438 Ph: (813) 974-2201	Dr Joseph Frank Michalski, MD, MPH, MS 820 S Wood St, Chicago, IL 60612-4325 Ph: (516) 497-1888

News Archive

Guilt plays a vital role in the regulation of social behavior

That worried feeling in our gut often serves as the impetus for our stab at redemption. However, psychologists have trouble agreeing on the function of this complex emotion.

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.

Researchers find evidence for precise communication across brain areas during sleep

By listening in on the chatter between neurons in various parts of the brain, researchers from the California Institute of Technology (Caltech) have taken steps toward fully understanding just how memories are formed, transferred, and ultimately stored in the brain-and how that process varies throughout the various stages of sleep.

MiMedx pleased with FDA Draft Guidance on Minimal Manipulation of HCT/Ps

MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, commented on the Draft Guidance for Industry on Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products ("HCT/Ps") that the Food and Drug Administration ("FDA") published for comment on December 23, 2014.

SARS-CoV-2 variants of concern drive up infections by 15-40 percent in Germany

As the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to distress worldwide, new variants are emerging that threaten the possibility of containment by current vaccines or therapeutic antibodies.

Dr Joseph Frank Michalski, MD, MPH, MS - Medicare Student in an Organized Health Care Education/Training Program in Chicago, IL